S. Africa hauls up India's Ranbaxy over bacteria found in folic acid tablets

Indian drug manufacturer Ranbaxy Laboratories was warned and asked to account by the South African government after finding a potentially harmful active ingredient in folic acid tablets sold by the company. 

The discovery led to 18,000 containers recalled in December 2015 after it was discovered folic acid tablets produced by Ranbaxy Laboratories also contained anti-inflammatory drug Betacin, which has potential for harm, according to Livemint.

A detailed report has been requested by the Medicines Control Council of South Africa to be delivered within a month, the report states.

Folic acid tablets, also known as vitamin B9, are usually prescribed to pregnant women to help prevent birth defects in a baby's spinal cord and brain.

Indomethacin, the active ingredient in Betacin, has the potential to not only affect pregnant women who are prescribed the drug, but also the babies, a drug regulator in South Africa told Livemint.

Ranbaxy was acquired by Indian multinational pharmaceutical company, Mumbai-based Sun Pharmaceutical Industries in April 2014 for $4 billion. Sun Pharmaceutical Industries has yet to comment on the matter, but has confirmed the request for a detailed report.

- here's the report from Livemint

Related Articles:
Sun Pharma said to be in talks to buy Intas for $2.3B
India's Sun Pharmaceutical takes another Ranbaxy-related hit
India's Sun Pharma looks to exit nonstrategic businesses
 

Suggested Articles

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

A decree includes tax incentives for certain generic drugmakers and uniform insurance standards that apply to both branded drugs and generics.